---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-034277"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2024-08-02T23:59:59+00:00"
generated_at: "2026-05-31T13:27:56.113417+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M

## Summary
- Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.
- Net loss GAAP $85.6M ($1.47/sh) includes $45M Biopharma impairment; adjusted net loss $40.6M.
- Adjusted EBITDA improved to $(22.0)M from $(29.6)M YoY; orders grew to $85.3M.
- FY2024 revenue guidance raised to ~$310-311M; gross margin guidance ~42% (high end).
- SynBio revenue $33.0M, NGS $43.4M, Biopharma $5.1M; cash $289.4M.

## SEC filing metadata
- accession: 0001628280-24-034277
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2024-08-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/0001628280-24-034277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828024034277/twist-20240802.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-034277
- JSON: https://secwatch.observer/filing/0001628280-24-034277.json
- Plain text: https://secwatch.observer/filing/0001628280-24-034277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.